Published in Cancer Biol Med on September 01, 2015
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
A Phase 1/2 Study to Evaluate MEDI4736 | NCT01693562
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | NCT02239900
AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466
Ipilimumab and Lenalidomide in Advanced Cancer | NCT01750983
Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res (2016) 0.77
Detection of circulating tumor cells in non-small cell lung cancer. J Thorac Dis (2016) 0.77
AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. J Cancer (2016) 0.76
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
Aesthetic Surgery in Patients with Lung Cancer: A Paradigm Shift. Plast Reconstr Surg Glob Open (2016) 0.75
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov (2016) 0.75
Immunotherapy in Cancer: Incremental Gain or a Quantum Leap? Oman Med J (2017) 0.75
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2017) 0.75
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Cancer immunology. N Engl J Med (2008) 5.22
Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol (1995) 3.06
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori (2012) 2.55
Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer (2014) 2.54
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14
In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One (2012) 1.44
MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine. JAMA Surg (2014) 1.42
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med (2011) 1.27
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother (2011) 1.19
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res (2011) 1.18
Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res (2015) 1.18
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol (2013) 1.15
VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res (2014) 1.09
Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy (2012) 1.07
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res (2013) 1.05
Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol (2012) 1.02
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 1.00
Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant (2007) 0.97
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer (2011) 0.97
Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J (2013) 0.95
The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother (2009) 0.92
MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg (1999) 0.89
NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology (2015) 0.84
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol (2015) 0.83
The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Res (2015) 0.81
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines (2011) 0.78
Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity. PLoS One (2013) 0.78